Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Introduction
  • The ECM as a driver of fibrosis progression
  • ECM composition in progressive organ fibrosis
  • ECM mechanical properties
  • ECM spatial heterogeneity and mechanotransduction in fibrosis
  • Modeling ECM mechanotransduction in fibrosis
  • Does ECM contribute to a fibrogenic niche in progressive fibrosis?
  • A tissue atlas as a possible way forward
  • Acknowledgments
  • Footnotes
  • References
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Review Series Free access | 10.1172/JCI93557

Extracellular matrix as a driver of progressive fibrosis

Jeremy Herrera, Craig A. Henke, and Peter B. Bitterman

Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.

Address correspondence to: Peter B. Bitterman, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, 420 Delaware Street SE, Pulmonary MMC 276, Minneapolis, Minnesota 55455, USA. Phone: 612.626.3773; E-mail: bitte001@umn.edu.

Find articles by Herrera, J. in: PubMed | Google Scholar

Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.

Address correspondence to: Peter B. Bitterman, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, 420 Delaware Street SE, Pulmonary MMC 276, Minneapolis, Minnesota 55455, USA. Phone: 612.626.3773; E-mail: bitte001@umn.edu.

Find articles by Henke, C. in: PubMed | Google Scholar

Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.

Address correspondence to: Peter B. Bitterman, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, 420 Delaware Street SE, Pulmonary MMC 276, Minneapolis, Minnesota 55455, USA. Phone: 612.626.3773; E-mail: bitte001@umn.edu.

Find articles by Bitterman, P. in: PubMed | Google Scholar

Published January 2, 2018 - More info

Published in Volume 128, Issue 1 on January 2, 2018
J Clin Invest. 2018;128(1):45–53. https://doi.org/10.1172/JCI93557.
Copyright © 2018, American Society for Clinical Investigation
Published January 2, 2018 - Version history
View PDF
Abstract

The extracellular matrix (ECM) is dynamically tuned to optimize physiological function. Its major properties, including composition and mechanics, profoundly influence cell biology. Cell-ECM interactions operate through an integrated set of sensor and effector circuits that use several classes of receptors and signal transduction pathways. At the single-cell level, the ECM governs differentiation, metabolism, motility, orientation, proliferation, and survival. At the cell population level, the ECM provides higher-order guidance that is essential for physiological function. When pathological changes in the ECM lead to impairment of organ function, we use the term “fibrosis.” In this Review, we differentiate fibrosis initiation from progression and focus primarily on progressive lung fibrosis impairing organ function. We present a working model to explain how the altered ECM is not only a consequence but also a driver of fibrosis. Additionally, we advance the concept that fibrosis progression occurs in a fibrogenic niche that is composed of a fibrogenic ECM that nurtures fibrogenic mesenchymal progenitor cells and their fibrogenic progeny.

Introduction

As a group, fibrotic disorders of the heart, blood vessels, lungs, kidney, liver, and other organs account for more than a third of the annual death rate in industrialized countries (1). Fibroproliferation is integral to host defense. Rapid closure of an integumentary or visceral wound is essential for restoration of tissue and organ integrity. Control of resistant intracellular pathogen infections is accomplished by formation of a dense circumferential scar. When fibroproliferation ensues after a single discrete injury, the process can be reversible or result in a durable scar comprising highly cross-linked collagens and other extracellular matrix (ECM) components. Examples of reversibility include many instances of integumentary wounding (2) and acute lung injury when the cause is controlled (3, 4). Durable fibrosis follows myocardial infarction (5) and tuberculosis (6). Sustained fibroproliferation, commonly designated as aberrant wound healing, frequently occurs after repetitive or persistent injurious stimuli. Examples include alcoholic cirrhosis, hypertension-induced kidney fibrosis, autoimmune disease, and uncontrolled chronic infection. In each of these circumstances, injury triggers a canonical coagulation/innate/adaptive immune response (7). Fibroproliferation ceases or regresses when the injurious stimulus is successfully mitigated or terminated or when the immune response is pharmacologically modulated or spontaneously abates. However, studies of idiopathic pulmonary fibrosis (IPF), a relentlessly progressive disorder, have revealed mechanisms of fibrosis progression that can be self-sustaining once established (8, 9). This indicates that fibrosis initiation and progression can be uncoupled. As a relatively new concept in the field of fibrosis, this Review will primarily focus on self-sustaining aspects of progressive fibrosis, emphasizing studies of the lung with examples from other organ systems.

The ECM as a driver of fibrosis progression

Progressive fibrosis remains one of the most vexing problems in modern medicine. Its seeming intractability does not result from a lack of scientific attention. Instead, we suspect that the formulation guiding even the best studies may be incomplete. Most experimental work has been guided by inferences from the advanced state of knowledge about fibrosis that follows a discrete injury, not by studies focused on self-sustaining progressive fibrosis as a discrete entity. As is the case for cancer biology, conceptually separating fibrosis initiation from fibrosis progression may enable the field to move forward. An extensive body of work across several organs implicates parenchymal cell injury with activation of the TGF-β pathway in disease initiation (10–12). This line of investigation continues to provide increasingly precise information about the molecular mechanisms leading to parenchymal cell attrition, setting the stage for fibroproliferation (13, 14).

In parallel with our increased understanding of fibrosis initiation, we have learned that fibrosis progression involves both cell-intrinsic/autonomous and ECM-driven mechanisms. Cell-autonomous fibrogenicity was initially identified in studies using primary mesenchymal cells from fibrotic tissue and organs (15–20), corroborated in zebrafish and mouse xenograft models (21, 22), and verified in mouse lineage tracing studies (23). The discovery of fibrogenic mesenchymal progenitor cells (MPCs) in the lungs of patients with IPF provided definitive proof in humans (9, 24). A role for individual ECM components and fragments as drivers of fibrosis progression has been firmly established for several decades. Fragments of fibrin, fibronectin, and hyaluronan are all potentially fibrogenic (25). More recent studies have provided new insights into ECM-mediated positive-feedback loops using decellularized lung ECM from patients with IPF (8, 26). In the absence of exogenous cytokines, IPF ECM alone induces normal lung fibroblasts to become activated myofibroblasts and to downregulate microRNA-29 (miR-29), a master negative regulator of stromal genes. Once formed, IPF ECM sets up a profibrotic feedback loop that is capable of sustaining progressive fibrosis (Figure 1). Increased substratum stiffness activates the mechanosensitive Hippo pathway effector Yes-associated protein 1 (YAP). Active YAP, in turn, upregulates ECM deposition and stiffness, constituting another positive-feedback loop (27). In MPCs, increased stiffness mediates acquisition of mechanical memory by causing a sustained increase of miR-21, a positive regulator of ECM deposition (28). Thus, although the evidence across all organs is incomplete, available data support the idea that progressive fibrosis in the absence of ongoing injury occurs in a fibrogenic niche comprising fibrogenic progenitors and their fibrogenic progeny residing in an ECM that is itself fibrogenic.

ECM-mediated feedback loops during fibrosis initiation and progression.Figure 1

ECM-mediated feedback loops during fibrosis initiation and progression. (Upper) Tissue injury leads to TGF-β activation and downstream canonical and noncanonical signals that initiate fibrosis. Once initiated, fibrosis can progress in the absence of the initial stimulus. (Lower) The fibrotic ECM can suppress miR-29, a master negative regulator of stromal genes. This results in increased ribosome recruitment to hundreds of stromal genes and sustained deposition of ECM, thus constituting a positive-feedback loop. Increased matrix stiffness activates the Hippo pathway effector Yes-associated protein 1 (YAP), which can drive ECM deposition and matrix stiffening, constituting another positive-feedback loop. Mesenchymal progenitor cell mechanical memory of substratum stiffness is mediated by miR-21, allowing these progenitors to stably maintain their fibrogenic phenotype and further stiffen the ECM.

In the text that follows, we consider the ECM in progressive fibrosis as part of a fibrogenic niche and focus on ECM characteristics that may generate and sustain fibrogenic mesenchymal progenitors and their progeny. The ECM characteristics we consider are composition and mechanical properties, both of which can have profound effects on cell biology. Our goal is to help illuminate a way forward toward a more complete understanding of self-sustaining progressive fibrosis. The reader is referred to other Reviews in this series for more details about the cell of origin in fibrotic disorders (29). We also refer the reader to the many excellent reviews of fibrosis initiation and fibrosis progression in the wake of a sustained or repetitive injury; and to reviews detailing the important emerging field of fibrosis reversibility (30, 31), where studies of liver fibrosis reversal after eradication of hepatitis C virus are leading the way.

ECM composition in progressive organ fibrosis

The ECM microenvironment provides cells with physical support for adhesion and cues that regulate position, cell cycle, metabolism, and differentiated state (32). The ECM is a major source of biochemical and biomechanical signals that are transduced and integrated to determine tissue organization and function. In general, excessive ECM production and aberrant ECM turnover characterize progressive organ fibrosis. In addition, dysregulation of ECM remodeling enzymes causes disorganization of ECM structure and ECM fragmentation, resulting in pathological cellular functions that contribute to fibrosis progression (33). Since ECM deposition and remodeling are dynamic processes during fibrosis progression, a comprehensive understanding of the spatial and temporal alterations in ECM composition is essential to fully elucidate the mechanisms underlying the progression of organ fibrosis. To illustrate, we will focus on the spatial-temporal heterogeneity of the ECM and cells characterizing the fibroblastic focus in IPF.

Myofibroblast core. Progressive fibrosis often has a characteristic pattern in each organ (34–37). We will focus on the pattern and polarity of fibrosis in the progressive fibrotic lung disease IPF, where recent studies provide insight into mechanism. In IPF, mesenchymal cells and their ECM products expand the alveolar wall, resulting in distortion and loss of the gas-exchange surface. The process begins at the bases and subpleural regions of the lungs and advances centripetally and apically (38). Studies of the IPF matrisome using mass spectrometry indicate that the IPF ECM is enriched for hyaluronan, latent TGF-β–binding protein 1, periostin, versican, fibulin, fibrillin, and a variety of collagens (26). However, how these alterations in ECM composition vary both regionally and temporally as IPF progresses remains incompletely understood.

Current understanding of the spatial-temporal heterogeneity in the IPF lung has been inferred from immunohistochemical analyses, which have been pivotal in elucidating regional differences in ECM composition and organization. More than 25 years ago, a seminal morphological investigation using a monoclonal antibody specific for pro–collagen I revealed that the myofibroblast core of the fibroblastic focus is the site of active ECM deposition (39). The myofibroblast core in IPF is enriched with fibrillar type I and III collagens, extra domain A fibronectin (EDA fibronectin), and fibrin; whereas the presence of type IV collagen varies (40). The myofibroblast core is also enriched with type VI collagen (41), the migratory moieties fascin and tenascin C (42), hyaluronan (43), and TGF-β (44).

Building on this foundation, recent work clarifies some of the molecular details in IPF. Indeed, the fibroblastic focus is a polarized structure composed of a mitotically active fibrotic front containing MPCs and their progeny, as well as a myofibroblast core region containing noncycling myofibroblasts actively synthesizing type I collagen (Figure 2 and ref. 9). The mechanism underlying the excessive collagen deposition by myofibroblasts involves fibrotic ECM-mediated suppression of miR-29, a master negative regulator of ECM genes (8). Thus, once formed, fibrotic ECM sets up a positive profibrotic feedback loop that stimulates further ECM production. TGF-β is expressed within the myofibroblast core (39, 44), and TGF-β stimulates the expression of EDA fibronectin, which promotes myofibroblast differentiation (45). In addition to fibrillar collagen and EDA fibronectin, glycosaminoglycans (GAGs) and versican are also abundant within the myofibroblast core (43). Versican is a chondroitin sulfate proteoglycan that promotes a variety of fibrogenic cellular functions, including proliferation, motility, and invasion (46). Importantly, the deposition of proteoglycans and GAGs alters the viscoelastic properties of the lung ECM, which in turn are capable of regulating fibroblast biology (47).

Polarity of the IPF Fibroblastic Focus.Figure 2

Polarity of the IPF Fibroblastic Focus. (A) The fibroblastic focus in IPF is polarized. It contains an active fibrotic front, which is a highly cellular region composed of proliferating fibrogenic MPCs, and activated macrophages embedded in a hyaluronan-rich ECM. The myofibroblast core contains noncycling myofibroblasts actively synthesizing collagen embedded in an ECM rich in collagen I/III/VI, fibronectin, fibrin, fascin, tenascin C, hyaluronan, and latent TGF-β. (B) An example of what is likely a newly developing fibroblastic focus (boxed region) at the advancing fibrotic front at the interface between fibrotic lung on the left and relatively uninvolved lung on the right. (C) Higher-power image of the boxed region in panel B showing the myofibroblast core and the active fibrotic front. At the periphery of the focus, thickened alveolar walls are juxtaposed between the active fibrotic front and morphologically preserved thin alveolar structures (indicated by arrows). This appearance supports a model of fibrosis progression in which cells in the active fibrotic front invade into contiguous morphologically preserved alveolar structures, causing progressive fibrotic destruction of the gas-exchange surface. The mesenchymal cells behind the fibrotic front (the progeny of IPF MPCs) differentiate into myofibroblasts that constitute the fibrotic core. Images adapted from Xia et al. (9).

The active fibrotic front. The active fibrotic front is found at the perimeter of the myofibroblast core in a highly cellular area between the myofibroblast core and relatively preserved alveolar structures. It contains proliferating, fibrogenic MPCs and their progeny together with activated macrophages (9, 48). Hyaluronan is abundantly expressed in the IPF lung (41), including the progenitor-rich perimeter region, and is known to be an important component of the stem/progenitor cell niche in health and disease. It is tempting to speculate that in the IPF active fibrotic front, the presence of hyaluronan might support the fibrogenic MPC pool, thus serving as an integral component of the fibrogenic niche. Expansion of self-renewing MPCs and their transit-amplifying progeny, together with recruitment of immune-modulatory cells, might lead to enlargement of adjacent alveolar walls en route to forming another myofibroblast core. In addition, hyaluronan stimulates invasion and overexpression of hyaluronic acid synthase 2 by mesenchymal cells, which confers them with an invasive phenotype (49). Disruption of CD44, a major hyaluronan receptor, inhibits mesenchymal cell invasiveness. These data support a model of fibrosis progression in which hyaluronan nurtures MPCs and stimulates mesenchymal cells within the active fibrotic front to invade adjacent uninvolved alveolar walls and mediate progressive fibrotic lung destruction. As a group, these studies highlight how regional differences in ECM composition can create a niche that regulates cellular phenotype and drives fibrotic progression.

Although the ECM can direct cell biology in a manner that either facilitates tissue repair or drives pathological remodeling, there is also evidence that during fibrosis progression, mesenchymal cells with autonomous behavior can emerge (50). Autonomous functions include the ability to elude physiological signals that mediate negative feedback provided by the ECM. For example, during physiological tissue repair, polymerized type I collagen ligates the α2β1 integrin to activate the antimitotic tumor suppressor phosphatase PTEN to limit cell proliferation (51). In contrast, in IPF, altered integrin signaling fails to increase PTEN, allowing unfettered activation of the PI3K/Akt signaling pathway. This permits IPF lung mesenchymal cells to escape the proliferation-suppressive effects of polymerized collagen that normally terminate collagen deposition by fibroblasts (17, 51) and activate apoptosis (52, 53). These data indicate that at some point during the course of fibrosis progression, mesenchymal cells can acquire a distinct and durable fibrogenic phenotype such that they no longer respond to the ECM cues that would typically terminate a fibrotic response. Most of the molecular details of how a durable fibrogenic phenotype is acquired remain to be elucidated; however, the acquisition of fibrogenic mechanical memory in response to ECM stiffness in a miR-21–dependent manner is one mechanism (28). Thus, once in motion, fibrosis progression is biologically robust. Fibrogenic ECM corrupts the miR-29 and miR-21 axes in cells still dependent on exogenous signals, and cell-autonomous fibrogenic MPCs produce fibrogenic daughter cells that differentiate to become activated myofibroblasts.

There are intriguing parallels between the ECM compositions of the invasive cancer front, the active fibrotic front, and the myofibroblast core in IPF. Like in IPF, hyaluronan accumulates in cancer tissues, where it supports cancer stem cell function (54) and cancer cell proliferation, motility, and viability (55). Hyaluronan cross-links with a variety of other ECM molecules, including versican, which itself cross-links with type I collagen, fibulin, fibrillin, and fibronectin to facilitate tumor cell invasion (56). The ECM of the invasive breast cancer front is characterized by collagen deposition, linearization, and thickening, together with an abundance of activated macrophages and high TGF-β activity (57). These findings support the view that during breast cancer progression, collagen deposition and linearization are linked to immune cell infiltration and activation of TGF-β. The similarities between the ECM of the invasive cancer front and the active fibrotic front of IPF align with the idea that common alterations in ECM composition and structure underlie the progressive nature of these diseases. Parallels with cancer remain to be explored in IPF and other organs undergoing progressive fibrosis.

A possible fibrogenic niche in cirrhosis. The pattern of cirrhosis following liver injury depends on the causative agent. Fibrosis begins in the portal tracts in chronic hepatitis C virus (HCV) infection and around the central vein in alcoholic liver disease. In chronic HCV infection, fibrosis progression manifests as fibrotic septa extending from portal tracts that connect to create bridging fibrosis. Each bridge is composed of fibrotic ribbons that interconnect branches of portal tracts. A proteomics approach applied to human HCV-infected liver has defined the ECM composition of bridging fibrosis, the phase of the disease that characterizes the transition from moderate to severe fibrosis (58). In cirrhosis, the space of Disse (the perisinusoidal region containing plasma and hepatic stellate cells [HSCs]) and portal tracts are sites of myofibroblast accumulation and ECM deposition. These myofibroblast-rich regions are replete with fibrillar type I and III collagens (59), fibronectin (60), and type V and VI collagen (61). Type IV collagen expression is variable and codistributes with laminin (62, 63). Increased expression of the migratory marker tenascin C has been found within the space of Disse and portal ducts (64). Hyaluronan is codistributed with α-smooth muscle actin–expressing cells within portal tracts (65), and TGF-β is expressed within fibrous septa (66). These studies highlight similarities of ECM composition within the myofibroblast-rich regions in lung and liver fibrosis, consistent with the idea of some shared underlying mechanisms.

Although speculative, it is possible to extend the concept of the fibrogenic niche to cirrhosis. Fate-tracing experiments suggest that HSCs may be a source of fibrogenic fibroblasts in some liver fibrosis models (67), although the evidence remains inconclusive (68, 69). Although not considered true progenitors, HSCs share properties with mesenchymal progenitors, including the capacity for tri-lineage differentiation (70, 71). HSCs reside in a perisinusoidal location in the space of Disse (72, 73), which, as a working hypothesis, can be conceptualized as a putative fibrogenic niche. Activated HSCs appear in increased numbers in regions of perisinusoidal fibrosis and bridging fibrosis. Like IPF MPCs, HSCs undergo differentiation to activated myofibroblasts in response to cytokines (74) and increased ECM stiffness (35, 36).

ECM mechanical properties

A hallmark of fibrotic tissue is an increase in its elastic modulus (stiffness). In human fibrosis of the lung (26, 27), liver (75, 76), kidney (77, 78), and vasculature (79), the ECM on average becomes stiffer than normal. Mechanotransduction of ECM stiffness plays important biological roles. Mechanotransduction pathways impact such critical cellular functions as proliferation, differentiation, and migration (32). Here we focus specifically on how mechanotransduction of ECM cues might influence fibrosis progression. The reader is referred to another Review in this series for a more comprehensive consideration of mechanotransduction in fibrosis (80).

One prominent mechanism for mechanotransduction of ECM stiffness operates through the Hippo pathway effector YAP. This mechanism serves to illustrate some principles underlying mechanotransduction of ECM inputs. Cell-ECM and cell-cell interactions play key roles in regulating YAP activity. Cell-ECM interactions are mediated predominantly by integrins, proteoglycan receptors, and their ligands at sites of focal adhesions where a variety of sensor proteins (e.g., focal adhesion kinase [FAK], talin, vinculin, the non-receptor tyrosine kinase SRC) interpret ECM mechanics and elicit downstream signaling responses (81). Cell-cell interactions operating through E-cadherin at sites of adherens/tight junctions modulate a cascade of protein signaling components that integrate and interpret mechanical inputs (82). Increased ECM stiffness can drive fibroblast ECM production in a YAP-dependent manner (27), and YAP expression has been identified in fibrosis of the lung (27), liver (83), and polycystic kidney disease (84) in humans. Enforced YAP expression in experimental animal models of lung fibrosis drives fibrosis progression (27). In addition, treatment with a pharmacological inhibitor of YAP function inhibits fibrosis in a fibrogenic kidney injury model (85); and YAP suppression in liver injury models reduces fibrosis (83). In the context of cancer stroma, cancer-associated fibroblasts express active YAP, which is required for ECM stiffening and maintenance of their pathological functions (86). These studies indicate that mechanotransduction of ECM stiffness mediated through YAP has the ability to serve as an integral component of the molecular mechanism for fibrosis progression.

ECM spatial heterogeneity and mechanotransduction in fibrosis

On average, fibrotic tissue is stiffer than healthy tissue. However, reassessment of reported stiffness of human fibrotic tissue compared with healthy tissue reveals substantial overlaps in the distributions of elastic moduli; in some cases, these necessitate large sample sizes to discern average stiffness differences in lung (26) and liver (87). One group reports nonsignificant elastic modulus differences comparing healthy and fibrotic human kidneys (88). In part, these data likely reflect the striking spatial heterogeneity of the ECM in fibrotic organs. This is relevant because current efforts to test the importance of increased ECM stiffness in fibrosis progression are hampered by the limited availability of regional mechanical data. We currently lack information about the mechanical properties of densely scarred regions versus the myofibroblast core versus the active fibrotic front versus relatively preserved areas in any form of organ fibrosis.

Cirrhosis assumes a variety of morphological patterns that are dependent on etiology: portal-portal, portal-central, and central-central septa (89). To date, few studies have used atomic force microscopy (AFM) to measure the elastic modulus of human liver tissue (90), and none have registered the mechanical properties of the ECM to specific morphological patterns in the cirrhotic liver. It will be important to understand the precise mechanical properties sensed by each type of cell within each region of each morphological pattern to develop the most clinically relevant models of fibrosis progression in an etiology- and pattern-specific manner.

IPF is composed of a multifocal network of fibroblastic foci that stand as independent structures ranging from 1.3 × 104 to 9.9 × 107 m3 (91). Fibroblastic foci are polarized structures with a myofibroblast core that actively produce ECM adjacent to normal alveolar structures (9). It is therefore likely that there are stiffness gradients along the fibroblastic focus, a steep stiffness gradient between the focus and adjacent normal structures, and another gradient between the focus and regions dominated by dense collections of ECM. Available AFM data from the IPF lung indicate that stiffness gradients span very short distances (26); however, there are no published data systematically registering elastic modulus to specific morphological regions, the fibroblastic focus, transitional alveoli with the earliest signs of thickening and cellular infiltration, adjacent uninvolved alveoli, or mature scar. The prevailing assumption in the field is that the cells within the fibroblastic focus sense a pathologically stiff ECM that drives fibrosis progression (26, 27, 92, 93). A critical knowledge gap in the field of progressive fibrosis is the exact stiffness a cell senses in situ as fibrosis progresses and which receptors and transduction pathways are involved.

Modeling ECM mechanotransduction in fibrosis

A seminal study showed that MSCs cultured on a stiff 2-dimensional (2D) substratum activate YAP (94), spurring a line of investigation that used a variety of biomaterials with well-defined properties to model how cells respond to mechanical stimuli (95). In addition to stiffness, key ECM properties that can modulate cell biology include dimensionality, viscoelasticity, and cyclic stretch. Moreover, cell-cell interactions can influence the response to both static and dynamic mechanical properties. To focus the discussion, control of YAP will serve as the example.

Dimensionality. In MSCs on a 2D substratum, ECM stiffness drives YAP translocation from the cytoplasm (inactive YAP) to the nucleus (active YAP) (94). However, in most tissues and organs, the cells enveloped in a fibrotic ECM experience a 3D environment. To examine the impact of dimensionality, investigators created hydrogels with tunable stiffness and cultured MSCs either on a 2D planar surface or embedded within a 3D hydrogel (96). In the 2D system, increasing stiffness drove YAP activation, whereas in the 3D system, exactly the opposite occurred, with stiffness promoting YAP inactivation. This report demonstrates the important role played by substratum dimensionality in cellular mechanosensing of ECM stiffness.

Viscoelasticity. Not only do cells perceive the difference between a 2D and a 3D environment, but they also sense changes in ECM viscoelasticity (stress-relaxation), defined as the force exerted by the ECM to maintain its original structure followed by its relaxation. When MSCs are cultured in 2D or 3D hydrogels in which both stiffness and viscoelasticity can be tuned, increasing viscoelasticity inactivates YAP independent of elastic modulus and dimensionality (97, 98).

Cyclic stretch. All organs undergo cyclic stretch with the periodicity of pulsatile blood flow (1 to 3 Hz). The lungs have the superimposed periodicity of the respiratory cycle, which varies by nearly an order of magnitude comparing healthy lungs with late-stage fibrotic lungs (0.1 vs. 1 Hz at rest). Thus, another mechanical property to account for is the mechanical strain caused by stretch. For example, mammary epithelial cells activate YAP in response to cyclic stretch, which promotes their proliferation (99). Cyclic stretch-compression can also regulate miR-29 and thereby collagen expression in periodontal ligament cells (100).

Cell-cell interactions. A more complete model of how cells interact with their ECM will account for cell-cell interactions. To illustrate, a hyaluronic acid hydrogel system was developed that enabled the independent copresentation of the HAVDI adhesive motif from N-cadherin (simulating cell-cell interactions) and the RGD adhesive motif from fibronectin (simulating cell-ECM interactions) to MSCs across a physiological range of ECM stiffness (101). An increase in HAVDI ligation with RGD ligation held constant led to reduced nuclear YAP localization with resultant modulation of cell proliferation and differentiation. Mechanistically, there was a reduction in contractile force generation due to the ability of N-cadherin ligation to dampen the Rac1-GTP/myosin IIA/focal adhesion signaling axis triggered by integrin ligation (101).

Mechanotransduction of ECM stiffness is one important mechanical property in fibrosis progression. However, the studies cited above, which track YAP activity in the context of ECM stiffness, dimensionality, viscoelasticity, cyclic stretch, and cell-cell interactions, demonstrate the importance of accounting for multiple parameters when constructing a model of the in vivo biology of progressive fibrosis. It is important to note that other mechanosensitive pathways also intersect with YAP signaling networks. For instance, mechanotransduction through Notch generates signals that form a positive-feedback loop with YAP. This feedback loop can be inhibited by Wnt/β-catenin signaling (102). It will be important to determine how other mechanotransduction pathways (103), such as FAK, ROCK/RhoA, and actin cytoskeletal rearrangements, are altered by ECM cues. Thus, a clinically relevant model of ECM mechanosensing will need to account for a network of inputs and signaling pathways.

Does ECM contribute to a fibrogenic niche in progressive fibrosis?

One provisional model for the stereotypical anatomic patterns of progressive fibrosis is that the actively developing lesions constitute a fibrogenic niche. In our proposed model, these niches are to be distinguished from regions dominated by highly cross-linked type I collagen, and regions yet to be enveloped by fibrosis. The ECM in the fibrogenic niche is compartmentalized, with its composition and mechanical properties organized in a manner that nurtures, supports, and guides all of the cells that mediate fibrosis progression: self-renewing MPCs, actively proliferating transit-amplifying cells, and pathological myofibroblasts that persist and actively secrete ECM. This model has been applied and tested in IPF, in which all of these cell populations can be found in situ in distinct regions of highly polarized fibroblastic foci. However, a detailed analysis of the lung ECM in the niche compared with adjacent regions has not been conducted. In the liver, HSCs display some progenitor cell characteristics (70, 71). Whether all HSCs can serve this role or only a subpopulation can function as progenitors remains to be determined. Similarly, whether the properties of the ECM in the regions where HSCs undergo self-renewal differ from those where differentiation into activated myofibroblasts occurs is an open question. We currently lack fine-mapping data defining ECM composition, organization, and mechanics related to their fibrogenic properties. Thus, we regard the concept of a distinct fibrogenic niche with fibrogenic progenitors as the source of activated myofibroblasts in progressive lung and liver fibrosis not as fact, but as one working model to guide future experiments.

A key feature of progressive fibrosis in all of these settings is the robustness of the fibrotic process. Indeed, many of the forces that initiate fibrosis persist as fibrosis progresses. These include epithelial stress, activated TGF-β, activated macrophages, and growth factors for fibroblasts. What may distinguish self-limited fibrosis after injury (i.e., the canonical process of fibroproliferation that is critical for repair and regeneration) from progressive fibrosis in the apparent absence of ongoing injury is an inflection point or a singularity in an otherwise well-behaved negative-feedback system. At this point of departure from negative feedback, many or all of the canonical fibrosis drivers become dispensable. We refer to this as cell-autonomy in the same sense as cancer is cell-autonomous; the cells from these lesions are fibrogenic in fibrosis or tumorigenic in cancer. To extend the analogy, as in cancer, in vivo progression in fibrosis is a pernicious dance between the ECM and the intrinsically pathological cells. In both IPF and cancer, compelling data implicate cell-ECM collaboration as integral to the robustness of disease progression.

A tissue atlas as a possible way forward

There is compelling evidence that fibrotic ECM is chemically, topographically, and mechanically distinct from ECM in healthy tissue. Fibrosis varies dynamically in time and space and assumes stereotypical patterns of progression in each organ. Moreover, a variety of cell types across a spectrum of proliferative, differentiated, and activated states participate in fibrosis progression. What are lacking are data to integrate all of this disparate but critical information. To date, no study in any human fibrotic disorder has coregistered ECM mechanical properties, orientation, and composition with cell identity and relevant parameters of cell biology. Thus, despite advances in the field of fibrosis, we lack an agreed-upon model of fibrosis progression. In our opinion, the database for such a model of fibrosis progression could take the form of a tissue atlas. A comprehensive tissue atlas would combine static and dynamic mechanical measurements, ECM composition and organization, cell identity, cell differentiated state, and cell biology (e.g., proliferation markers, signaling footprints) at both micron and millimeter resolution, registered region by region according to key morphological features in human fibrosis (Figure 3).

Tissue atlas: 3-D reconstruction of a fibrogenic niche coregistering mechanFigure 3

Tissue atlas: 3-D reconstruction of a fibrogenic niche coregistering mechanics, ECM composition, cell identity, and cell biology. Shown is a conceptual schematic of a tissue atlas using IPF as an example. Images adapted from Jones et al. (91). A comprehensive tissue atlas would combine — at both the micron and millimeter scale of resolution — static and dynamic mechanical measurements, data regarding ECM composition and organization, cell identity, cell differentiated state, and cell biology (e.g., proliferation markers, signaling footprints). These data would be registered region by region to key morphological features: myofibroblast core and active fibrotic front. With such a data set, investigators would be positioned to generate testable models that pinpoint targetable pathways critical to fibrosis progression based on (a) the precise mechanical properties a cell is sensing, (b) the ECM components a cell is interacting with, and (c) the resulting cell biology as a function of those inputs. Addition of MALDI-imaging mass spectrometry to the picture could provide unprecedented insights into progressive fibrosis (105, 106).

Imaging technology and computing power have advanced to the point where it is feasible to tackle this undertaking. As an example, in studying the morphology of fibroblastic foci in IPF about a decade ago, investigators used early-generation 3D reconstruction algorithms to conclude that fibroblastic foci in IPF formed a large interconnected fibrotic reticulum (104). Recently, more advanced 3D reconstruction approaches revealed that fibroblastic foci are serpiginous independent structures, not interconnected — a fact with important mechanical implications (91). Adding cell biology and detailed ECM information to facilitate accurate modeling of these lesions is one path toward a much deeper mechanistic understanding of fibrotic progression. With such a data set, investigators would be positioned to generate testable models that pinpoint targetable pathways critical to fibrosis progression based on (a) the precise mechanical properties a cell is sensing; (b) the ECM components that the cell interacts with; and (c) the resulting cell biology as a function of these inputs. Such a study could pave the way forward for the creation of a model that recapitulates the in vivo biology and generate data-driven hypotheses aimed at unveiling the molecular mechanisms mediating fibrosis progression. We view this as one important step toward a strategic drug discovery program designed to interdict progressive fibrosis.

Acknowledgments

This work was supported by NIH grants T32HL077410 (to JH), R01H125227 (to CAH), and R01HL125236 (to PBB).

Address correspondence to: Peter B. Bitterman, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, 420 Delaware Street SE, Pulmonary MMC 276, Minneapolis, Minnesota 55455, USA. Phone: 612.626.3773; E-mail: bitte001@umn.edu.

Footnotes

Conflict of interest: The authors have declared that no conflict of interest exists.

Reference information: J Clin Invest. 2018;128(1):45–53.https://doi.org/10.1172/JCI93557.

References
  1. Rockey DC, Bell PD, Hill JA. Fibrosis — a common pathway to organ injury and failure. N Engl J Med. 2015;373(1):96.
    View this article via: CrossRef Google Scholar
  2. Desmoulière A, Badid C, Bochaton-Piallat ML, Gabbiani G. Apoptosis during wound healing, fibrocontractive diseases and vascular wall injury. Int J Biochem Cell Biol. 1997;29(1):19–30.
    View this article via: PubMed CrossRef Google Scholar
  3. Kapanci Y, Weibel ER, Kaplan HP, Robinson FR. Pathogenesis and reversibility of the pulmonary lesions of oxygen toxicity in monkeys. II. Ultrastructural and morphometric studies. Lab Invest. 1969;20(1):101–118.
    View this article via: PubMed Google Scholar
  4. Polunovsky VA, et al. Role of mesenchymal cell death in lung remodeling after injury. J Clin Invest. 1993;92(1):388–397.
    View this article via: JCI PubMed CrossRef Google Scholar
  5. Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res. 2016;119(1):91–112.
    View this article via: PubMed CrossRef Google Scholar
  6. Hunter RL. Tuberculosis as a three-act play: a new paradigm for the pathogenesis of pulmonary tuberculosis. Tuberculosis (Edinb). 2016;97:8–17.
    View this article via: PubMed CrossRef Google Scholar
  7. Henson PM. Dampening inflammation. Nat Immunol. 2005;6(12):1179–1181.
    View this article via: PubMed CrossRef Google Scholar
  8. Parker MW, et al. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest. 2014;124(4):1622–1635.
    View this article via: JCI PubMed CrossRef Google Scholar
  9. Xia H, et al. Calcium-binding protein S100A4 confers mesenchymal progenitor cell fibrogenicity in idiopathic pulmonary fibrosis. J Clin Invest. 2017;127(7):2586–2597.
    View this article via: JCI PubMed CrossRef Google Scholar
  10. Ahluwalia N, Shea BS, Tager AM. New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. Am J Respir Crit Care Med. 2014;190(8):867–878.
    View this article via: PubMed CrossRef Google Scholar
  11. Friedman SL, Sheppard D, Duffield JS, Violette S. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med. 2013;5(167):167sr1.
    View this article via: PubMed Google Scholar
  12. Henderson NC, et al. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013;19(12):1617–1624.
    View this article via: PubMed CrossRef Google Scholar
  13. Young LR, et al. Epithelial-macrophage interactions determine pulmonary fibrosis susceptibility in Hermansky-Pudlak syndrome. JCI Insight. 2016;1(17):e88947.
    View this article via: JCI Insight PubMed Google Scholar
  14. Liang J, et al. Hyaluronan and TLR4 promote surfactant-protein-C-positive alveolar progenitor cell renewal and prevent severe pulmonary fibrosis in mice. Nat Med. 2016;22(11):1285–1293.
    View this article via: PubMed CrossRef Google Scholar
  15. Diegelmann RF, Cohen IK, McCoy BJ. Growth kinetics and collagen synthesis of normal skin, normal scar and keloid fibroblasts in vitro. J Cell Physiol. 1979;98(2):341–346.
    View this article via: PubMed CrossRef Google Scholar
  16. Wilborn J, Crofford LJ, Burdick MD, Kunkel SL, Strieter RM, Peters-Golden M. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest. 1995;95(4):1861–1868.
    View this article via: JCI PubMed CrossRef Google Scholar
  17. Xia H, et al. Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis. J Exp Med. 2008;205(7):1659–1672.
    View this article via: PubMed CrossRef Google Scholar
  18. Rodemann HP, Müller GA. Abnormal growth and clonal proliferation of fibroblasts derived from kidneys with interstitial fibrosis. Proc Soc Exp Biol Med. 1990;195(1):57–63.
    View this article via: PubMed CrossRef Google Scholar
  19. Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol. 2011;8(1):42–54.
    View this article via: PubMed CrossRef Google Scholar
  20. Galambos JT, Hollingsworth MA, Falek A, Warren WD, McCain JR. The rate of synthesis of glycosaminoglycans and collagen by fibroblasts cultured from adult human liver biopsies. J Clin Invest. 1977;60(1):107–114.
    View this article via: JCI PubMed CrossRef Google Scholar
  21. Pierce EM, et al. Therapeutic targeting of CC ligand 21 or CC chemokine receptor 7 abrogates pulmonary fibrosis induced by the adoptive transfer of human pulmonary fibroblasts to immunodeficient mice. Am J Pathol. 2007;170(4):1152–1164.
    View this article via: PubMed CrossRef Google Scholar
  22. Benyumov AO, Hergert P, Herrera J, Peterson M, Henke C, Bitterman PB. A novel zebrafish embryo xenotransplantation model to study primary human fibroblast motility in health and disease. Zebrafish. 2012;9(1):38–43.
    View this article via: PubMed CrossRef Google Scholar
  23. Rinkevich Y, et al. Skin fibrosis. Identification and isolation of a dermal lineage with intrinsic fibrogenic potential. Science. 2015;348(6232):aaa2151.
    View this article via: PubMed CrossRef Google Scholar
  24. Xia H, et al. Identification of a cell-of-origin for fibroblasts comprising the fibrotic reticulum in idiopathic pulmonary fibrosis. Am J Pathol. 2014;184(5):1369–1383.
    View this article via: PubMed CrossRef Google Scholar
  25. Genovese F, Karsdal MA. Protein degradation fragments as diagnostic and prognostic biomarkers of connective tissue diseases: understanding the extracellular matrix message and implication for current and future serological biomarkers. Expert Rev Proteomics. 2016;13(2):213–225.
    View this article via: PubMed CrossRef Google Scholar
  26. Booth AJ, et al. Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med. 2012;186(9):866–876.
    View this article via: PubMed CrossRef Google Scholar
  27. Liu F, et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am J Physiol Lung Cell Mol Physiol. 2015;308(4):L344–L357.
    View this article via: PubMed CrossRef Google Scholar
  28. Li CX, et al. MicroRNA-21 preserves the fibrotic mechanical memory of mesenchymal stem cells. Nat Mater. 2017;16(3):379–389.
    View this article via: PubMed Google Scholar
  29. Di Carlo SE, Peduto L. The perivascular origin of pathological fibroblasts. J Clin Invest. 2018;128(1):54–63.
  30. Jun JI, Lau LF. Resolution of organ fibrosis. J Clin Invest. 2018;128(1):97–107.
  31. Vinaixa C, Strasser SI, Berenguer M. Disease reversibility in patients with post-Hepatitis C cirrhosis: is the point of no return the same before and after liver transplantation? A review. Transplantation. 2017;101(5):916–923.
    View this article via: PubMed CrossRef Google Scholar
  32. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014;15(12):786–801.
    View this article via: PubMed Google Scholar
  33. Mouw JK, Ou G, Weaver VM. Extracellular matrix assembly: a multiscale deconstruction. Nat Rev Mol Cell Biol. 2014;15(12):771–785.
    View this article via: PubMed Google Scholar
  34. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998;157(4 pt 1):1301–1315.
    View this article via: PubMed Google Scholar
  35. Hoofring A, Boitnott J, Torbenson M. Three-dimensional reconstruction of hepatic bridging fibrosis in chronic hepatitis C viral infection. J Hepatol. 2003;39(5):738–741.
    View this article via: PubMed CrossRef Google Scholar
  36. et al. Structural-functional relationships in diabetic nephropathy. J Clin Invest. 1984;74(4):1143–1155.
    View this article via: JCI PubMed CrossRef Google Scholar
  37. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209–218.
    View this article via: JCI PubMed CrossRef Google Scholar
  38. Raghu G, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
    View this article via: PubMed CrossRef Google Scholar
  39. Kuhn C, McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol. 1991;138(5):1257–1265.
    View this article via: PubMed Google Scholar
  40. Kuhn C, Boldt J, King TE, Crouch E, Vartio T, McDonald JA. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis. 1989;140(6):1693–1703.
    View this article via: PubMed CrossRef Google Scholar
  41. Specks U, Nerlich A, Colby TV, Wiest I, Timpl R. Increased expression of type VI collagen in lung fibrosis. Am J Respir Crit Care Med. 1995;151(6):1956–1964.
    View this article via: PubMed CrossRef Google Scholar
  42. Chilosi M, et al. Migratory marker expression in fibroblast foci of idiopathic pulmonary fibrosis. Respir Res. 2006;7:95.
    View this article via: PubMed Google Scholar
  43. Bensadoun ES, Burke AK, Hogg JC, Roberts CR. Proteoglycan deposition in pulmonary fibrosis. Am J Respir Crit Care Med. 1996;154(6 pt 1):1819–1828.
    View this article via: PubMed Google Scholar
  44. Broekelmann TJ, Limper AH, Colby TV, McDonald JA. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci U S A. 1991;88(15):6642–6646.
    View this article via: PubMed CrossRef Google Scholar
  45. Serini G, et al. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol. 1998;142(3):873–881.
    View this article via: PubMed CrossRef Google Scholar
  46. Ricciardelli C, Sakko AJ, Ween MP, Russell DL, Horsfall DJ. The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev. 2009;28(1–2):233–245.
    View this article via: PubMed Google Scholar
  47. Venkatesan N, et al. Glycosyltransferases and glycosaminoglycans in bleomycin and transforming growth factor-β1-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2014;50(3):583–594.
    View this article via: PubMed CrossRef Google Scholar
  48. Yang L, et al. IL-8 mediates idiopathic pulmonary fibrosis mesenchymal progenitor cell fibrogenicity. [published online ahead of print August 31, 2017]. Am J Pathol. https://doi.org/10.1152/ajplung.00200.2017.
    View this article via: PubMed CrossRef Google Scholar
  49. Li Y, et al. Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. J Exp Med. 2011;208(7):1459–1471.
    View this article via: PubMed CrossRef Google Scholar
  50. Noble PW, Barkauskas CE, Jiang D. Pulmonary fibrosis: patterns and perpetrators. J Clin Invest. 2012;122(8):2756–2762.
    View this article via: JCI PubMed CrossRef Google Scholar
  51. Xia H, et al. Low α(2)β(1) integrin function enhances the proliferation of fibroblasts from patients with idiopathic pulmonary fibrosis by activation of the β-catenin pathway. Am J Pathol. 2012;181(1):222–233.
    View this article via: PubMed CrossRef Google Scholar
  52. Nho RS, Hergert P. IPF fibroblasts are desensitized to type I collagen matrix-induced cell death by suppressing low autophagy via aberrant Akt/mTOR kinases. PLoS One. 2014;9(4):e94616.
    View this article via: PubMed CrossRef Google Scholar
  53. Nho RS, Peterson M, Hergert P, Henke CA. FoxO3a (Forkhead Box O3a) deficiency protects idiopathic pulmonary fibrosis (IPF) fibroblasts from type I polymerized collagen matrix-induced apoptosis via caveolin-1 (cav-1) and Fas. PLoS One. 2013;8(4):e61017.
    View this article via: PubMed CrossRef Google Scholar
  54. Borovski T, De Sousa E Melo F, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res. 2011;71(3):634–639.
    View this article via: PubMed CrossRef Google Scholar
  55. Schwertfeger KL, Cowman MK, Telmer PG, Turley EA, McCarthy JB. Hyaluronan, inflammation, and breast cancer progression. Front Immunol. 2015;6:236.
    View this article via: PubMed Google Scholar
  56. Varga I, et al. Brevican, neurocan, tenascin-C and versican are mainly responsible for the invasiveness of low-grade astrocytoma. Pathol Oncol Res. 2012;18(2):413–420.
    View this article via: PubMed CrossRef Google Scholar
  57. Acerbi I, et al. Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr Biol (Camb). 2015;7(10):1120–1134.
    View this article via: PubMed CrossRef Google Scholar
  58. Baiocchini A, et al. Extracellular matrix molecular remodeling in human liver fibrosis evolution. PLoS One. 2016;11(3):e0151736.
    View this article via: PubMed CrossRef Google Scholar
  59. Grimaud JA, Druguet M, Peyrol S, Chevalier O, Herbage D, El Badrawy N. Collagen immunotyping in human liver: light and electron microscope study. J Histochem Cytochem. 1980;28(11):1145–1156.
    View this article via: PubMed CrossRef Google Scholar
  60. Hahn E, Wick G, Pencev D, Timpl R. Distribution of basement membrane proteins in normal and fibrotic human liver: collagen type IV, laminin, and fibronectin. Gut. 1980;21(1):63–71.
    View this article via: PubMed CrossRef Google Scholar
  61. Mak K. Codistribution of collagens V and VI with collagens I and III in hepatic fibrosis of elderly cadavers. FASEB J. 2015;29(1 Suppl):544.4.
  62. Mak KM, Chu E, Lau KH, Kwong AJ. Liver fibrosis in elderly cadavers: localization of collagen types I, III, and IV, α-smooth muscle actin, and elastic fibers. Anat Rec (Hoboken). 2012;295(7):1159–1167.
    View this article via: PubMed CrossRef Google Scholar
  63. Mak KM, Chen LL, Lee TF. Codistribution of collagen type IV and laminin in liver fibrosis of elderly cadavers: immunohistochemical marker of perisinusoidal basement membrane formation. Anat Rec (Hoboken). 2013;296(6):953–964.
    View this article via: PubMed CrossRef Google Scholar
  64. Van Eyken P, Sciot R, Desmet VJ. Expression of the novel extracellular matrix component tenascin in normal and diseased human liver. An immunohistochemical study. J Hepatol. 1990;11(1):43–52.
    View this article via: PubMed CrossRef Google Scholar
  65. Ichida T, et al. Localization of hyaluronan in human liver sinusoids: a histochemical study using hyaluronan-binding protein. Liver. 1996;16(6):365–371.
    View this article via: PubMed Google Scholar
  66. Bedossa P, Peltier E, Terris B, Franco D, Poynard T. Transforming growth factor-β1 (TGF-β1) and TGF-β1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology. 1995;21(3):760–766.
    View this article via: PubMed Google Scholar
  67. Mederacke I, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013;4:2823.
    View this article via: PubMed Google Scholar
  68. Tarlow BD, Finegold MJ, Grompe M. Clonal tracing of Sox9+ liver progenitors in mouse oval cell injury. Hepatology. 2014;60(1):278–289.
    View this article via: PubMed CrossRef Google Scholar
  69. Schaub JR, Malato Y, Gormond C, Willenbring H. Evidence against a stem cell origin of new hepatocytes in a common mouse model of chronic liver injury. Cell Rep. 2014;8(4):933–939.
    View this article via: PubMed CrossRef Google Scholar
  70. Kordes C, Sawitza I, Götze S, Herebian D, Häussinger D. Hepatic stellate cells contribute to progenitor cells and liver regeneration. J Clin Invest. 2014;124(12):5503–5515.
    View this article via: JCI PubMed CrossRef Google Scholar
  71. Kordes C, Sawitza I, Götze S, Häussinger D. Hepatic stellate cells support hematopoiesis and are liver-resident mesenchymal stem cells. Cell Physiol Biochem. 2013;31(2–3):290–304.
    View this article via: PubMed Google Scholar
  72. Olsen AL, et al. Hepatic stellate cells require a stiff environment for myofibroblastic differentiation. Am J Physiol Gastrointest Liver Physiol. 2011;301(1):G110–G118.
    View this article via: PubMed CrossRef Google Scholar
  73. Guvendiren M, Perepelyuk M, Wells RG, Burdick JA. Hydrogels with differential and patterned mechanics to study stiffness-mediated myofibroblastic differentiation of hepatic stellate cells. J Mech Behav Biomed Mater. 2014;38:198–208.
    View this article via: PubMed CrossRef Google Scholar
  74. Mews P, et al. Pancreatic stellate cells respond to inflammatory cytokines: potential role in chronic pancreatitis. Gut. 2002;50(4):535–541.
    View this article via: PubMed CrossRef Google Scholar
  75. Mueller S, Sandrin L. Liver stiffness: a novel parameter for the diagnosis of liver disease. Hepat Med. 2010;2:49–67.
    View this article via: PubMed Google Scholar
  76. Zhao G, et al. Mechanical stiffness of liver tissues in relation to integrin β1 expression may influence the development of hepatic cirrhosis and hepatocellular carcinoma. J Surg Oncol. 2010;102(5):482–489.
    View this article via: PubMed CrossRef Google Scholar
  77. Stock KF, et al. ARFI-based tissue elasticity quantification in comparison to histology for the diagnosis of renal transplant fibrosis. Clin Hemorheol Microcirc. 2010;46(2–3):139–148.
    View this article via: PubMed Google Scholar
  78. Arndt R, et al. Noninvasive evaluation of renal allograft fibrosis by transient elastography — a pilot study. Transpl Int. 2010;23(9):871–877.
    View this article via: PubMed Google Scholar
  79. Briones AM, Arribas SM, Salaices M. Role of extracellular matrix in vascular remodeling of hypertension. Curr Opin Nephrol Hypertens. 2010;19(2):187–194.
    View this article via: PubMed CrossRef Google Scholar
  80. Tschumperlin DJ, Ligresti G, Hilscher MB, Shah VH. Mechanosensing and fibrosis. J Clin Invest. 2018;128(1):74–84.
    View this article via: JCI PubMed Google Scholar
  81. DuFort CC, Paszek MJ, Weaver VM. Balancing forces: architectural control of mechanotransduction. Nat Rev Mol Cell Biol. 2011;12(5):308–319.
    View this article via: PubMed CrossRef Google Scholar
  82. Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer. 2013;13(4):246–257.
    View this article via: PubMed CrossRef Google Scholar
  83. Mannaerts I, et al. The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. J Hepatol. 2015;63(3):679–688.
    View this article via: PubMed CrossRef Google Scholar
  84. Happé H, et al. Altered Hippo signalling in polycystic kidney disease. J Pathol. 2011;224(1):133–142.
    View this article via: PubMed CrossRef Google Scholar
  85. Szeto SG, et al. YAP/TAZ are mechanoregulators of TGF-β-Smad signaling and renal fibrogenesis. J Am Soc Nephrol. 2016;27(10):3117–3128.
    View this article via: PubMed CrossRef Google Scholar
  86. Calvo F, et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol. 2013;15(6):637–646.
    View this article via: PubMed CrossRef Google Scholar
  87. Coco B, et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat. 2007;14(5):360–369.
    View this article via: PubMed CrossRef Google Scholar
  88. Syversveen T, Midtvedt K, Berstad AE, Brabrand K, Strøm EH, Abildgaard A. Tissue elasticity estimated by acoustic radiation force impulse quantification depends on the applied transducer force: an experimental study in kidney transplant patients. Eur Radiol. 2012;22(10):2130–2137.
    View this article via: PubMed CrossRef Google Scholar
  89. Karsdal MA, et al. Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2015;308(10):G807–G830.
    View this article via: PubMed CrossRef Google Scholar
  90. Saneyasu T, Akhtar R, Sakai T. Molecular cues guiding matrix stiffness in liver fibrosis. Biomed Res Int. 2016;2016:2646212.
    View this article via: PubMed Google Scholar
  91. Jones MG, et al. Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis. JCI Insight. 2016;1(5):e86375.
    View this article via: JCI Insight PubMed Google Scholar
  92. Marinković A, Liu F, Tschumperlin DJ. Matrices of physiologic stiffness potently inactivate idiopathic pulmonary fibrosis fibroblasts. Am J Respir Cell Mol Biol. 2013;48(4):422–430.
    View this article via: PubMed CrossRef Google Scholar
  93. Huang X, et al. Matrix stiffness-induced myofibroblast differentiation is mediated by intrinsic mechanotransduction. Am J Respir Cell Mol Biol. 2012;47(3):340–348.
    View this article via: PubMed CrossRef Google Scholar
  94. Dupont S, et al. Role of YAP/TAZ in mechanotransduction. Nature. 2011;474(7350):179–183.
    View this article via: PubMed CrossRef Google Scholar
  95. Caliari SR, Burdick JA. A practical guide to hydrogels for cell culture. Nat Methods. 2016;13(5):405–414.
    View this article via: PubMed CrossRef Google Scholar
  96. Caliari SR, Vega SL, Kwon M, Soulas EM, Burdick JA. Dimensionality and spreading influence MSC YAP/TAZ signaling in hydrogel environments. Biomaterials. 2016;103:314–323.
    View this article via: PubMed CrossRef Google Scholar
  97. Chaudhuri O, et al. Hydrogels with tunable stress relaxation regulate stem cell fate and activity. Nat Mater. 2016;15(3):326–334.
    View this article via: PubMed Google Scholar
  98. Chaudhuri O, et al. Substrate stress relaxation regulates cell spreading. Nat Commun. 2015;6:6364.
    View this article via: PubMed Google Scholar
  99. Codelia VA, Sun G, Irvine KD. Regulation of YAP by mechanical strain through Jnk and Hippo signaling. Curr Biol. 2014;24(17):2012–2017.
    View this article via: PubMed CrossRef Google Scholar
  100. Chen Y, et al. Cyclic stretch and compression forces alter microRNA-29 expression of human periodontal ligament cells. Gene. 2015;566(1):13–17.
    View this article via: PubMed CrossRef Google Scholar
  101. Cosgrove BD, et al. N-cadherin adhesive interactions modulate matrix mechanosensing and fate commitment of mesenchymal stem cells. Nat Mater. 2016;15(12):1297–1306.
    View this article via: PubMed CrossRef Google Scholar
  102. Kim W, et al. Hippo signaling interactions with Wnt/β-catenin and Notch signaling repress liver tumorigenesis. J Clin Invest. 2017;127(1):137–152.
    View this article via: JCI PubMed CrossRef Google Scholar
  103. Duscher D, et al. Mechanotransduction and fibrosis. J Biomech. 2014;47(9):1997–2005.
    View this article via: PubMed CrossRef Google Scholar
  104. Cool CD, Groshong SD, Rai PR, Henson PM, Stewart JS, Brown KK. Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med. 2006;174(6):654–658.
    View this article via: PubMed CrossRef Google Scholar
  105. Cornett DS, Reyzer ML, Chaurand P, Caprioli RM. MALDI imaging mass spectrometry: molecular snapshots of biochemical systems. Nat Methods. 2007;4(10):828–833.
    View this article via: PubMed CrossRef Google Scholar
  106. Aichler M, Walch A. MALDI imaging mass spectrometry: current frontiers and perspectives in pathology research and practice. Lab Invest. 2015;95(4):422–431.
    View this article via: PubMed CrossRef Google Scholar
Version history
  • Version 1 (January 2, 2018): Print issue publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Review Series

Fibrosis

  • The fibrotic tumor stroma
    Mitsuo Yamauchi et al.
  • Fibroblast heterogeneity: implications for human disease
    Magnus D. Lynch et al.
  • Insights from human genetic studies of lung and organ fibrosis
    Christine Kim Garcia
  • Extracellular matrix as a driver of progressive fibrosis
    Jeremy Herrera et al.
  • The perivascular origin of pathological fibroblasts
    Selene E. Di Carlo et al.
  • Endoplasmic reticulum stress in the pathogenesis of fibrotic disease
    Jonathan A. Kropski et al.
  • Mechanosensing and fibrosis
    Daniel J. Tschumperlin et al.
  • The balancing act of the liver: tissue regeneration versus fibrosis
    Lucía Cordero-Espinoza et al.
  • Resolution of organ fibrosis
    Joon-Il Jun et al.

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Introduction
  • The ECM as a driver of fibrosis progression
  • ECM composition in progressive organ fibrosis
  • ECM mechanical properties
  • ECM spatial heterogeneity and mechanotransduction in fibrosis
  • Modeling ECM mechanotransduction in fibrosis
  • Does ECM contribute to a fibrogenic niche in progressive fibrosis?
  • A tissue atlas as a possible way forward
  • Acknowledgments
  • Footnotes
  • References
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts